Environments and social factors shape human microbiotas.
The abundance of Bifidobacterium may explain M116’s excellent cholesterol profile and low inflammation levels.
Arthur Ouwehand, Technical Fellow at IFF Finland, discusses the components and vulnerabilities of the gut barrier and reviews how probiotics and related dietary interventions can support its structure and function.
MaaT Pharma, based in Lyon and listed on Euronext Paris, unveiled the final results of its ARES Phase 3 trial of Xervyteg® (MaaT013).
New IPA Europe analysis puts hard numbers on how evidence-based probiotic use could cut healthcare costs and boost productivity across the EU.
The authors propose a coordinated framework involving policymakers, scientists, educators, and communities to embed microbiota science into One Health strategies.
Targeting gut bacteria or butyrate could be a promising therapy for glioma.
Akari Hiraku, researcher at Innovative Research Institute, Morinaga Milk Industry Co., presented clinical data on Bifidobacterium longum subsp. infantis M-63, a probiotic strain with a remarkable capacity to utilize HMOs.
Dietary fiber during early life protects fertility by supporting healthy gut microbes and preventing ovarian damage caused by high-fat diets.
Gut microbes could be a target for preventing kidney disease-related heart failure.
